Few parts of a prescribing information are read as carefully as the pregnancy sections, and few are summarized as carelessly. The GLP-1 labels handle the subject directly, in plain if clinical language, and in one respect they differ from each other in a way people planning a pregnancy deserve to know about. This article reports what the labels say, in their own terms, about planning a pregnancy and about being pregnant while taking one of these medicines. It is not advice about either.
Anyone already pregnant and taking one of these medicines for weight reduction gets one sentence here rather than a checklist: the labels instruct discontinuation when a pregnancy is recognized, and that is a conversation to have with the prescriber straight away rather than a decision to make from an article.
The two month instruction, and where it does not appear
The Wegovy label instructs prescribers to discontinue the medicine in patients at least 2 months before they plan to become pregnant, to account for the potential for fetal harm given the long half-life of semaglutide. The Ozempic label says the same in its own words: discontinue at least 2 months before a planned pregnancy, due to the long washout period.
The arithmetic behind the instruction is printed on the label. Semaglutide's elimination half-life is approximately one week, and the Wegovy label states that semaglutide will be present in the circulation for about 5 to 7 weeks after the last injectable dose of 2.4 mg. Two months is that tail, rounded up with room to spare. Why a week by week washout matters at all, and what the medication level is doing in those weeks, is the subject of Semaglutide Half-Life: Understanding Your Medication Level.
Then comes the part that surprises people: Zepbound and Mounjaro carry no such interval. Nothing in their pregnancy sections sets a time before a planned pregnancy. What their section 8.3 covers instead is contraception, a subject with its own chemistry and its own article. The absence of a two month instruction on the tirzepatide labels is a difference in what each label instructs, not a statement that one molecule is safer in pregnancy. A label records what was studied and what reviewers decided to require; it is not a ranking of molecules.
What the tirzepatide labels say instead
The Zepbound and Mounjaro pregnancy sections warn that use of the medicine may reduce the effectiveness of oral hormonal contraceptives because of delayed gastric emptying, that the delay is largest after the first dose and diminishes over time, and that patients using oral hormonal contraceptives should switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose escalation. The full mechanics, and the reasoning behind each clause, are laid out in Tirzepatide and the Pill: What the Label Says About Birth Control.
What the labels say about pregnancy itself
The Wegovy label states that, based on animal reproduction studies, there may be potential risks to the fetus from exposure to semaglutide during pregnancy, while available pharmacovigilance data and clinical trial data in pregnant patients are insufficient to establish a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Potential risk and insufficient human data: that is the register of the entire subject, and it is the register this article keeps.
The same label also states flatly that weight loss offers no benefit to a pregnant patient and may cause fetal harm. When a pregnancy is recognized, it instructs advising the pregnant patient of the risk to a fetus and discontinuing the medicine in patients using it for weight reduction. Zepbound says the same thing in its own words, advising pregnant patients that weight loss is not recommended during pregnancy and to discontinue when a pregnancy is recognized.
Zepbound adds a clinical consideration worth knowing exists: appropriate weight gain based on pre-pregnancy weight is currently recommended for all pregnant patients, including those with obesity or overweight, because of the obligatory weight gain that occurs in maternal tissues during pregnancy.
The MASH exception, and why it exists
For the weight reduction use, the Wegovy label instructs discontinuation outright. For the liver indication, it does not. It says that Wegovy for the treatment of MASH with advanced liver fibrosis should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and that whether treatment during pregnancy reduces the risks of the underlying liver disease is unknown. The reasoning is visible on the page: when a medicine treats a disease rather than weight, the label weighs a risk against a risk instead of against no benefit. The liver indication itself has a full article in GLP-1s and Fatty Liver: What the Trials Report.
GLP 1 Tracker AppA dated dose log answers the question every prescriber asks in this conversation: when was the last dose, and how have the weeks run.
Get the app
The animal studies, read carefully
The caution in these labels rests partly on animal reproduction studies, and those deserve exact reporting rather than paraphrase. In pregnant rats given semaglutide during organogenesis, embryofetal mortality, structural abnormalities and alterations to growth occurred at clinically relevant maternal exposures at the maximum recommended human dose. In pregnant rabbits and cynomolgus monkeys, early pregnancy losses and structural abnormalities were observed at clinically relevant exposures. The Wegovy label adds a clause that matters and should not be dropped: these findings coincided with a marked maternal body weight loss in both animal species.
The Zepbound animal data follows the same shape: fetal growth reductions and fetal abnormalities in rats, and fetal growth reductions in rabbits, with the label noting that these effects coincided with the drug's effects on maternal weight and food consumption.
Two readings are wrong in opposite directions. The animal findings are not proof of human harm; they are part of why the labels say potential risk rather than established risk. They are also not dismissible; they occurred at clinically relevant exposures, which is the standard that makes regulators pay attention. The labels' own framing, stated risk alongside acknowledged gaps in human data, is the honest one.
Background risk, registries and the appointment
For scale, the labels note that in the US general population, the estimated background risk of major birth defects in clinically recognized pregnancies is 2 to 4 percent, and of miscarriage is 15 to 20 percent. The Zepbound label adds that the estimated background risk for its indicated population is increased compared with the general population.
Both manufacturers run a pregnancy exposure registry that follows outcomes in people exposed to these medicines during pregnancy, and a clinician can point someone to the right one. When the conversation with a prescriber happens, the dates in a dose log are exactly what gets asked for: when the last dose was taken, and how the weeks have run since. Bringing that record, and making the appointment productive with it, is covered in Make Your Next Appointment Count: Bringing Data to the Doctor.
That is the whole of what an article can responsibly do here: report the labels, including where they differ, and point at the conversations that carry the decisions. The two month instruction on the semaglutide labels, the contraception guidance on the tirzepatide ones, and the plain sentence that weight loss offers no benefit to a pregnant patient are all prescriber material. The planning itself was never this article's to advise on, and it does not try.
Frequently asked questions
How long before pregnancy should semaglutide be stopped?
The Wegovy and Ozempic labels instruct discontinuation at least 2 months before a planned pregnancy, to account for the long washout of semaglutide: the elimination half-life is about one week, and the label states the drug will be present in the circulation for about 5 to 7 weeks after the last injectable dose of 2.4 mg. Whether and when to stop is a decision made with the prescriber, never from an article.
Do Mounjaro and Zepbound have the same 2 month rule?
No. The tirzepatide pregnancy sections set no pre-pregnancy interval. They address contraception instead: the medicines may reduce the effectiveness of oral hormonal contraceptives because of delayed gastric emptying, and the labels advise switching to a non-oral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose escalation. The difference is in what each label instructs, not in proven safety.
What do the labels say if you become pregnant on a GLP-1?
For the weight reduction use, the Wegovy and Zepbound labels instruct advising the patient of the potential risk and discontinuing the medicine when a pregnancy is recognized, and both state that weight loss offers no benefit to a pregnant patient and may cause fetal harm. The Wegovy MASH indication is handled differently, used in pregnancy only if the potential benefit justifies the potential risk. The next step is contacting the prescriber.
Is it safe to take a GLP-1 while pregnant?
The labels do not answer with a yes. Animal reproduction studies showed embryofetal mortality and structural abnormalities at clinically relevant exposures, while human data are insufficient to establish a drug associated risk, and the labels state that weight loss offers no benefit to a pregnant patient and may cause fetal harm. Apart from the MASH exception, the weight reduction labels instruct discontinuation when pregnancy is recognized. The decision belongs with a prescriber.
Why do the semaglutide labels say 2 months specifically?
Because of the washout. Semaglutide has an elimination half-life of about one week, so the medication level declines over weeks rather than days, and the Wegovy label states the drug is present in the circulation for about 5 to 7 weeks after the last injectable dose of 2.4 mg. Two months covers that tail with room to spare. The half-life itself has a plain English guide on this site.